NCT05082727 is a Phase 2 clinical trial of KOVIR (TD0068) oral softgel in COVID-19, sponsored by Sao Thai Duong Joint Stock Company.

Who is sponsoring NCT05082727?

NCT05082727 is sponsored by Sao Thai Duong Joint Stock Company.

What drugs are being tested in NCT05082727?

Interventions in NCT05082727: KOVIR (TD0068) oral softgel, Placebo oral softgel.

Is NCT05082727 still recruiting?

NCT05082727 is currently status unknown. Last updated 7 February 2022.

Last reviewed 2022-02-07 · How we verify

NCT05082727

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Softgel KOVIR (TD0068) in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR)

Status unknown Phase 2 Last updated 7 February 2022

What this trial tests

Phase 2 trial testing KOVIR (TD0068) oral softgel in COVID-19 in 60 participants. Status unknown.

Timeline

1 July 2021

Primary endpoint
15 September 2022

15 November 2022

Quick facts

Lead sponsor	Sao Thai Duong Joint Stock Company
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	1 July 2021
Primary completion	15 September 2022
Estimated completion	15 November 2022
Sites	1 location across Vietnam

Drugs / interventions tested

KOVIR (TD0068) oral softgel
Placebo oral softgel

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Sao Thai Duong Joint Stock Company — full company profile →

Who can join

Adults 18 to 65, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The acute pneumonia pandemic caused by a new strain of corona virus 2019 named as COVID-19 by the World Health Organization (WHO) is a pandemic caused by SARS-CoV-2 virus. The reported symptoms vary from fever or chills, cough, shortness of breath, to muscle aches, headaches, loss of taste or smell. The capsule KOVIR is a product based on the traditional medicine which is used to treat the cold conditions, also known as the initial plague according to the theory of traditional medicine.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Aged Garlic Extract (AGE) and Its Constituent S-Allyl-Cysteine (SAC) Inhibit the Expression of Pro-Inflammatory Genes Induced in Bronchial Epithelial IB3-1 Cells by Exposure to the SARS-CoV-2 Spike Protein and the BNT162b2 Vaccine.
Gasparello J, Papi C, Marzaro G, Macone A, et al · · 2024 · cited 6× · PMID 39770027 · DOI 10.3390/molecules29245938
Traditional Vietnamese Medicine Containing Garlic Extract for Patients With Non-severe COVID-19: A Phase-II, Double-Blind, Randomized Controlled Trial.
Giang TV, Hoa LNM, Hien TT, Cuong QD, et al · · 2023 · cited 2× · PMID 37637574 · DOI 10.7759/cureus.42484

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Sao Thai Duong Joint Stock Company trials

Trials by the same sponsor.

NCT05249777 — A Phase III, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TD0069 Capsule fo · Phase 3 · completed
NCT05042141 — Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR) · NA · completed
NCT03845959 — A Trial of TD0019 in Treatment of Cervical Scapulohumeral Syndrome · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05082727 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sao Thai Duong Joint Stock Company
Last refreshed: 7 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05082727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing